CNTB CNTB
Company Profile ↓Company Overview
CNTB (CNTB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $64.00K (-99.8% YoY); net profit $-55.48M.
- Trailing 12 Months Year-on-year growth — revenue -99.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -99.75% |
Stock Price Performance
| 1 Year: | +6.86% |
| 6 Months: | -17.74% |
| 3 Months: | -11.74% |
| 1 Month: | -1.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 40.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 24.12M | 1.22M | 0 | 48.00K | 16.00K | 169.00K |
| Operating Income | -12.63M | 13.65M | -13.85M | -11.45M | -13.42M | -17.68M | -19.61M |
| Net Income | -8.69M | 14.85M | -12.88M | -10.27M | -12.90M | -17.20M | -19.40M |
| Diluted EPS | -0.16 | 0.27 | -0.23 | -0.19 | -0.23 | -0.31 | -0.34 |
| R&D Expense | 8.66M | 5.35M | 9.01M | 6.63M | 8.77M | 11.11M | 15.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 26.03M | 64.00K |
| Operating Income | -69.06M | -22.45M | -58.07M |
| Net Income | -62.11M | -15.63M | -55.48M |
| Diluted EPS | -1.13 | -0.28 | -1.00 |
| R&D Expense | 53.00M | 29.26M | 37.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 127.38M | 101.28M | 56.08M |
| Total Equity | 158.42M | 101.50M | 92.17M | 41.98M |
| Cash & Equivalents | - | 105.66M | 78.23M | 38.34M |
| Total Liabilities | - | 25.88M | 9.12M | 14.10M |
| Current Liabilities | - | 25.29M | 8.46M | 13.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -47.74M | -23.61M | -51.21M |
| Investing Cash Flow | 74.98M | -3.45M | 9.82M |
| Financing Cash Flow | 45.00K | 227.00K | 1.09M |
| Capital Expenditure | -81.00K | -750.00K | -434.00K |
| Free Cash Flow | -47.82M | -24.36M | -51.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | -86.2% | -90,740.6% |
| Net Margin % | - | -60.0% | -86,687.5% |
| ROE % | -61.2% | -17.0% | -132.2% |
| ROCE % | -67.6% | -24.2% | -136.8% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNTB
$CNTB stock is up 22% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPQ25IT2hJajUtZFdmZU1xbDFPTHl6LVJqOEN4d0VTbGVJWEplTVhqNWRXcTl2ZHpSMjhFenh0b3dTdEZQSlFMS0FmTmJrQWdXdHFmNS03SGMwZ0FqUEZfT0dqV0hsN3EtdWsyNWNhaWpGSXd2aElMY1F6QmpUNkRKVXZ6M0plVEZVRzQwcm…
Connect Biopharma Holdings Limited Revenue Breakdown – NASDAQ:CNTB - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1vbzl0WlBoOVpoYzl2OVF3U1JKNWp6ZUNvODdiVkFVdUJuYksyQXFGanpsMDhwVGNfTUlSQTQ4Q2I1ODFGWEdrdGc1c1oyRjYyRTRTVFdKMDE5S3JLME9HS3Ezb3JTbjhUUmh5amZyd1Bxc1VpRTJ3?oc=5" target="_blank">Connect…
Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdlRmbmx5RF81UTJxLWVPc09hTUhhSlNqT3pzSl83VWFEUmp6YjBFRTBTTm9feHVaVWtJMDlHSUdNYWdXQ1hzWjQzT1AzNnp5MzRHdzlwbDU2MXBCdWdycWpsSmtSeXBCSVZZN01rRWlxdlJ0cEtDMnRFcU15T1A0M0pTUHB1UTB3N240cG…
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent (NASDAQ:CNTB) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNTE1oak9GcS1BR3RGVlNaTG9iMENva0NlLXY1XzdnV3NPV1ZMS3pZakVpNm1ld2tXT0tRTmN5ZGdiT1ZxekxMT3l5N0FSQ0VzdEtmbzlwU05OYk9wQ2JNSzVwMUlYNWFMT1VkOUFKYzBhRHFNOVJaRllJbHlhNVlXVXp5RllfelFQc0VITm…
CNTB|Connect Biopharma Holdings Ltd|Price:2.020|Chg%:-0.070 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1HUGVTMFczb2Y1VnV2WmVxbTNRdmFkSVAtamxoNmF3Qm1xQ2FzbFh0MzhsS3U1a0w3SXRKSm5na2JZNEN1cVZNa1hGS2J5b3h3aE4xeU11MTl4VkpkU0hwOWNHQUp5SWRnLXdmdTNB?oc=5" target="_blank">CNTB|Connect Biopha…
Here's Why Connect Biopharma Holdings (NASDAQ:CNTB) Must Use Its Cash Wisely - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQUUtjQVlhck9WMGpDLWprSlU5LWlnTEtQcVBOcDk4aUpjcTQ0OFNsWnFUajJCWGhyZnkzUVZHTmtpOVRjRFhtQ09seTFERklwTXcxXzduZTdjZlh4djdEVi1HUXF2SEFWcDlCZUpWbnkybDdHcU14dlBJQ0lrQ2VFVllBVlpRNWJydW9hX1…
CNTB — Frequently Asked Questions
What is the current share price of CNTB?
As of 2026-08-05 17:25 PDT, CNTB trades at $2.18 on NASDAQ/NYSE. Its 52-week range is $1.32 to $3.69.
What is the P/E ratio of CNTB?
CNTB trades at a trailing price-to-earnings (P/E) ratio of -2.18.
What is the return on equity (ROE) of CNTB?
CNTB has a return on equity (ROE) of -132.16%. Its return on capital employed (ROCE) is -136.77%.
Is CNTB a good stock to buy?
This page provides a data-driven analysis of CNTB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.